BRPI0408846A - compostos para o tratamento de infecções por flaviviridae - Google Patents

compostos para o tratamento de infecções por flaviviridae

Info

Publication number
BRPI0408846A
BRPI0408846A BRPI0408846-8A BRPI0408846A BRPI0408846A BR PI0408846 A BRPI0408846 A BR PI0408846A BR PI0408846 A BRPI0408846 A BR PI0408846A BR PI0408846 A BRPI0408846 A BR PI0408846A
Authority
BR
Brazil
Prior art keywords
virus
flaviviridae infections
compounds
treatment
infections
Prior art date
Application number
BRPI0408846-8A
Other languages
English (en)
Inventor
Lieven J Stuyver
Original Assignee
Pharmasset Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Inc filed Critical Pharmasset Inc
Publication of BRPI0408846A publication Critical patent/BRPI0408846A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTOS PARA O TRATAMENTO DE INFECçõES POR FLAVIVIRIDAE". A invenção descrita é uma composição para e um método de tratamento de infecções por Flaviviridae, tais como vírus da diarréia viral bovina (BVDV), vírus da Dengue (DENV), vírus do Nilo Oeste (WNV) vírus da hepatite C, assim como de proliferações celulares anormais, em um hospedeiro, incluindo animais, e humanos especialmente, utilizando um nucleosídeo de fórmula geral (I) - (V) ou N(fosfonoacetil)-L-aspartato (PALA) ou um sal ou pró-medicamento farmaceuticamente aceitável do mesmo.
BRPI0408846-8A 2003-03-28 2004-03-29 compostos para o tratamento de infecções por flaviviridae BRPI0408846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45863503P 2003-03-28 2003-03-28
PCT/IB2004/001429 WO2004084796A2 (en) 2003-03-28 2004-03-29 Compounds for the treatment of flaviviridae infections

Publications (1)

Publication Number Publication Date
BRPI0408846A true BRPI0408846A (pt) 2006-07-04

Family

ID=33098273

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408846-8A BRPI0408846A (pt) 2003-03-28 2004-03-29 compostos para o tratamento de infecções por flaviviridae

Country Status (10)

Country Link
US (1) US20050049204A1 (pt)
EP (1) EP1626692A4 (pt)
JP (1) JP2006524227A (pt)
CN (1) CN1980678A (pt)
AU (1) AU2004224575A1 (pt)
BR (1) BRPI0408846A (pt)
CA (1) CA2529311A1 (pt)
MX (1) MXPA05010419A (pt)
RU (1) RU2005133093A (pt)
WO (1) WO2004084796A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
US20090270431A1 (en) * 2005-10-19 2009-10-29 The University Of Georgia Research Foundation Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
BRPI0715714A2 (pt) * 2006-08-25 2014-03-11 Wyeth Corp Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
CN101511185A (zh) * 2006-09-11 2009-08-19 南方研究所 唑类核苷和作为rna和dna病毒聚合酶抑制剂的用途
KR101927905B1 (ko) * 2008-04-03 2018-12-11 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
CN102123706B (zh) 2008-06-17 2013-08-14 米纳斯吉拉斯联合大学 血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP3860591A4 (en) * 2018-10-04 2022-06-01 Octagon Therapeutics Inc. PRE-ACTIVATED NUCLEOSIDE IMPDH INHIBITORS AS ANTI-INFECTIVE DRUGS
CN114828859A (zh) * 2019-12-06 2022-07-29 南京明德新药研发有限公司 siRNA缀合物、双链siRNA缀合物及其盐和应用
US20230123911A1 (en) * 2020-01-31 2023-04-20 Octagon Therapeutics, Inc. Modulation of immune cells
TW202214855A (zh) * 2020-06-10 2022-04-16 大陸商正大天晴藥業集團股份有限公司 雙鏈siRNA類似物的共軛物
WO2023155909A1 (zh) * 2022-02-18 2023-08-24 南京明德新药研发有限公司 三氮唑核苷类似物及其作为嵌入基团的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
GB1414841A (en) * 1972-02-11 1975-11-19 Syntex Inc 2,5-anhydro-dalloses derivatives thereof and c-glycosylnucleosides derived therefrom
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
US5102883A (en) * 1989-10-31 1992-04-07 Du Pont Merck Pharmaceutical Company Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents
ZA931934B (en) * 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US20020137696A1 (en) * 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) * 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
NZ330784A (en) * 1996-01-23 1999-02-25 Icn Pharmaceuticals Modulation of th1/th2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
ATE271063T1 (de) * 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
US6455690B1 (en) * 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
HUP0001107A3 (en) * 1996-10-16 2003-01-28 Icn Pharmaceuticals Inc Costa Monocyclic l-nucleosides, analogs and pharmaceutical compositions thereof
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US6887707B2 (en) * 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
JP2001525797A (ja) * 1996-10-28 2001-12-11 ザ ユニバーシティ オブ ワシントン ウイルスｒｎａへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導
ZA9811726B (en) * 1997-12-22 1999-06-21 Schering Corp Orally administrable solid ribavirin dosage forms and process for making them
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
EA008609B1 (ru) * 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
MY129244A (en) * 1998-05-15 2007-03-30 Schering Corp Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection.
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
CA2346447C (en) * 1998-10-16 2006-01-31 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases
US6495677B1 (en) * 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7056895B2 (en) * 2000-02-15 2006-06-06 Valeant Pharmaceuticals International Tirazole nucleoside analogs and methods for using same
NZ521210A (en) * 2000-02-18 2004-11-26 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
CN100457118C (zh) * 2000-04-13 2009-02-04 法玛塞特有限公司 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) * 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1360325A2 (en) * 2000-10-18 2003-11-12 Pharmasset Limited Multiplex quantification of nucleic acids in diseased cells
PT1411954E (pt) * 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
MY134070A (en) * 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) * 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2005504087A (ja) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
JP2005536440A (ja) * 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
EP1536804A4 (en) * 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
BR0313164A (pt) * 2002-08-01 2007-07-17 Pharmasset Inc compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections

Also Published As

Publication number Publication date
RU2005133093A (ru) 2006-07-27
EP1626692A4 (en) 2008-12-10
MXPA05010419A (es) 2006-05-31
AU2004224575A1 (en) 2004-10-07
US20050049204A1 (en) 2005-03-03
WO2004084796A3 (en) 2006-04-06
JP2006524227A (ja) 2006-10-26
CA2529311A1 (en) 2004-10-07
CN1980678A (zh) 2007-06-13
WO2004084796A2 (en) 2004-10-07
EP1626692A2 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
BRPI0408846A (pt) compostos para o tratamento de infecções por flaviviridae
ATE491459T1 (de) Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
BRPI0410846A (pt) compostos, composições e usos para o tratamento de uma infecção por flaviviridae
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
SG161315A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BRPI0312547B8 (pt) uso de derivados de imidazo [4,5-c]piridina como inibidores virais
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
BR0311126A (pt) Composições e método para tratar infecção em gado bovino e em suìnos
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
BR0312278A (pt) éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
BR0307712A (pt) Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
DE69030732D1 (de) Antiparasitäre zusammensetzung zur verwendung bei tieren
ES2160977T3 (es) 1-fenilalquil-1,2,3,6-tetrahidropiridinas para el tratamiento de la enfermedad de alzheimer.
BRPI0509533A (pt) compostos de agentes antivirais, composição farmacêutica e seus usos
ATE374024T1 (de) Verwendung von 5-methoxytryptamin als kardioprotektives mittel

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE A DESPACHO 8.6 NA RPI 2159 DE 22/05/2012 E DESPACHO 8.11 NA RPI 2180 DE 16/10/2012.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADE(S), CONFORME ART. 10 DA RESOLUCAO 124/06 DA LPI 9.279.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2189 DE 18/12/2012.